[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"muscle-function\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:muscle-function":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,58,88,113,141,170,198,231],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":35,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100633575","the-effects-of-peptistrong-and-whey-on-muscle-function-in-older-adults-100633575",false,"NCT07528469","The Effects of PeptiStrong and Whey on Muscle Function In Older Adults","The Effects of PeptiStrong and Low Dose Whey Protein Versus High Dose Whey Protein Alone on Muscle Function In Older Adults","Inclusion Criteria:\n\n* Men and women aged 60 to 85 years at the time of enrolment\n* Community-dwelling (living independently or with minimal assistance)\n* Able to walk independently (with or without a walking aid) and complete simple physical function tests (such as standing up from a chair and walking short distances)\n* Willing and able to attend two study visits at the research facility (baseline and end of study)\n* Willing and able to consume a protein drink containing whey protein (derived from milk) once daily for 30 days\n* Able to understand the study information and provide written informed consent\n\nExclusion Criteria:\n\n* Any known food allergy or intolerance to fava bean protein or milk protein\n* Diagnosed kidney disease or any medical condition where increased protein intake is contraindicated\n* Yes to any of the answers on the \"Older Adult Functional Assessment Screening Questionnaire\"\n* Individuals with implanted electronic devices\n* Current or recent (within the past 3 months) participation in another clinical research study involving a nutritional or exercise intervention\n* Conditions that significantly impair mobility or balance such that safe completion of the physical function tests is not possible",true,"ALL","60 Years","85 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"NA","Examining the effects of PeptiStrong and protein on muscle function in older adults",[28,29,30,31,32,33,34],"Healthy Ageing","Protein Supplementation","Muscle Health","Muscle Function","Hand Grip Strength","Longevity","Peptides",[36,37,38,39,33,40,41,42,43,44],"Healthy Aging","Protein supplementation","Muscle function","Physical performance","Bioactive peptides","Hand grip strength","Short performance physical battery","Nuritas","Liverpool John Moore University","RECRUITING","2026-04-30",{"date":48,"type":49},"2026-05-06","ACTUAL",{"date":51,"type":49},"2026-04-06",{"date":53,"type":22},"2026-10-30",{"name":55,"class":56},"Nuritas Ltd","INDUSTRY",1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":4,"eligibilityCriteria":64,"healthyVolunteers":16,"sex":17,"minAge":65,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":23,"phases":68,"briefSummary":69,"conditions":70,"keywords":76,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":57},"100608713","a-randomized-controlled-trial-comparing-whole-body-vibration-therapy-with-usual-care-and-usual-care-to-improve-muscle-health-in-older-adults-100608713","NCT07205133","A Randomized Controlled Trial Comparing Whole Body Vibration Therapy With Usual Care and Usual Care to Improve Muscle Health in Older Adults","Effectiveness of Whole Body Vibration Therapy and Usual Care Compared to Usual Care in Improving Muscle Mass, Strength and Function in Older Adults","Inclusion Criteria:\n\n* Healthy Volunteer or Patients aged 65 and above,\n* Clinical frailty Scale (CFS) score of 3-4,\n* Independently ambulating without any aid\n* willingness and consent to participate in the study and ability to travel to the study-site for the measurements and interventions, and\n* participants with no regular exercise habits (defined as less than 150mins\u002Fweek of moderate intensity aerobic exercise and less than twice a week of strengthening exercises)for past 3 months.\n\nExclusion Criteria:\n\n* current active enrolment into any Day Rehab or community exercise program,\n* contraindications to WBVT machine usage (see below),\n* diagnosis of dementia,\n* history of Diabetes Mellitus\n* BMI ≤20kg\u002Fm2,\n* recent hospital admissions within the last 3 months,\n* end stage organ failure,\n* chronic diseases which are not well managed, for example, poorly controlled hypertension,\n* New York Heart Association (NYHA) score II and above for patients with history of heart failure and\n* MUST Score ≥1.\n\nContraindications to WBVT:\n\nPRIMARY CONTRAINDICATIONS TO WBVT\n\n* Pregnancy\n* Acute thrombosis (acute vascular occlusion)\n* Artificial joints in stimulated body regions\n* Fresh fractures in stimulated body regions\n* Within 3 months post surgery\u002Fprocedure and\u002For any fresh wounds and scars in the stimulated body regions\n* or if the wound healing is not yet completely finished.\n\nSECONDARY CONTRAINDICATIONS TO WBVT\n\n* Acute inflammation of the musculoskeletal system, activated arthrosis or\n* arthropathy (e.g. acute inflammation and swelling in joints).\n* Acute tendinopathies in stimulated body regions (acute tendonitis)\n* Acute hernias (tissue ruptures)\n* Acute discopathy (acute disc-related back problem)\n* Stone disease of the bile ducts and urinary tract\n* Rheumatoid Arthritis\n* Epilepsy due to secondary risk of injury","65 Years",{"count":67,"type":22},40,[25],"This study is a randomized controlled trial where participants would be randomly assigned to one of 2 groups. One group would receive Whole body vibration therapy and usual care and the other group only usual care. Measurements of muscle mass, strength and function would be taken before the interventions, and at 2 other points after interventions. Differences in the outcomes between the two groups would be analysed.",[71,72,73,74,31,75],"Aging","Frailty","Sarcopenia","Muscle Strength","Muscle Mass",[71,72,73,77,74,31,75],"Whole Body Vibration Therapy","2026-04-14",{"date":80,"type":49},"2026-04-15",{"date":82,"type":49},"2026-01-10",{"date":84,"type":22},"2027-03-31",{"name":86,"class":87},"Changi General Hospital","OTHER",{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":16,"sex":17,"minAge":96,"maxAge":65,"enrollmentInfo":97,"targetDuration":4,"studyType":23,"phases":99,"briefSummary":100,"conditions":101,"keywords":102,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":57},"100610761","the-effect-of-urolithin-a-mitopure-supplementation-on-muscle-strength-in-healthy-middle-aged-adults-100610761","NCT07231783","The Effect of Urolithin A (Mitopure®) Supplementation on Muscle Strength in Healthy Middle-Aged Adults","A Confirmatory, Randomised, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Effects of a Dietary Supplement Containing Urolithin A (Mitopure®) on Muscle Strength and Performance in Healthy Middle-Aged Adults","ATLAS 2","Inclusion Criteria:\n\n* 1\\. Be able to give written informed consent.\n* 2\\. Be between 40 to 65 years of age, inclusive.\n* 3\\. Has a BMI between 25.0 and 34.9 kg\u002Fm2.\n* 4\\. Low physical activity levels as assessed by the International Physical Activity Questionnaire (IPAQ).\n* 5\\. Participants with low VO2 peak (defined as \\\u003C35 mL\u002Fkg\u002Fmin via the ergometer prior to baseline).\n* 6\\. Willing to avoid exercising 48-h prior to study visits and maintain low physical activity status for the duration of the study.\n* 7\\. Willing to avoid caffeine and other stimulants (e.g., energy drinks) 12-h before exercise as per study guidelines.\n* 8\\. Willing to consume the Study Product daily for the duration of the study.\n\nExclusion Criteria:\n\n* 1\\. Participants who are pregnant or wish to become pregnant during the study or who are lactating and\u002For currently breastfeeding.\n* 2\\. Participants currently of biological childbearing potential, but not using a continuous effective method of contraception, as outlined below:\n\n  * a. Complete abstinence from intercourse two weeks prior to administration of the Study Product, throughout the clinical study, until the completion of follow-up procedures or for two weeks following discontinuation of the Study Product in cases where Participant discontinues the study prematurely. (Participants utilising this method must agree to use an alternate method of contraception if they should become sexually active and will be queried on whether they have been abstinent in the preceding two weeks when they present to the clinic for the final visit).\n  * b. Has a male sexual partner who is surgically sterilised prior to the Screening Visit and is the only male sexual partner for that Participant.\n  * c. Sexual partner(s) is\u002Fare exclusively female.\n  * d. Use of acceptable method of contraception, such as a spermicide, mechanical barrier (e.g., male condom, female diaphragm), tubal ligation, or contraceptive pill. The Participant must be using this method for at least one week prior to and one week following the end of the study.\n  * e. Use of any intrauterine device (IUD) or contraceptive implant. The Participant must have the device inserted at least two weeks prior to the first screening visit, throughout the study, and two weeks following the end of the study.\n* 3\\. Participants with history of drug and\u002For alcohol abuse at the time of enrolment. (Drinks more than nationally recommended units per week (\\>11 units for women; \\>17 units for men); alcohol\u002Fsubstance abuse disorder).\n* 4\\. Participants consuming large quantities of pomegranate juice or walnuts or frequent consumers of raspberries, strawberries or cloudberries (2-week washout).\n* 5\\. Chronic nicotine use.\n* 6\\. Participants who are unable to swallow capsules.\n* 7\\. Is hypersensitive to or has dietary restrictions for any of the components of the Study Product e.g., gelatine\n* 8\\. Unstable body weight or recent participation in a weight loss program (within 12-weeks prior to screening).\n* 9\\. Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the Participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history and routine laboratory test results. Excluded health conditions include:\n\n  * a. Major illness\u002Fsurgery in the 12-weeks prior to screening\n  * b. Diagnosed cardiovascular disease (NHYA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmia, uncontrolled hypertension)\n  * c. Diagnosed liver disease (cirrhosis, end stage liver disease)\n  * d. Diagnosed kidney disease (stage 3b or 4 chronic kidney disease, or kidney failure)\n  * e. Diagnosed gastrointestinal disease (IBS\u002FIBD, diarrhoea, Acid Reflux)\n  * f. Uncontrolled thyroid conditions\n  * g. Uncontrolled diabetes\n  * h. Metallic implants\n  * i. Conditions requiring chemotherapy or immunotherapy.\n* 10\\. Current or recent use of a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results. Prohibited medications include:\n\n  * a. Statins or other medications known to impair mitochondrial function.\n  * b. Anxiolytics, antidepressants, sedative hypnotics (in the 8 weeks prior to visit 1)\n  * c. Antipsychotics, monoamine Oxidase Inhibitors (in the 8 weeks prior to visit 1)\n  * d. Oral anti- infective (antibiotics, antivirals, antifungals) for acute infections (in the 12-weeks prior to visit 1)\n  * e. Proton pump inhibitors (PPIs) (in the 4 weeks prior to visit 1)\n  * f. Corticosteroids (\\> 5mg per day in the past 4 weeks prior to visit 1)\n  * g. GLP-1 agonists (in the 8 weeks prior to visit 1)\n* 11\\. Current or recent (in the past 6-weeks prior to Visit 1) use of prohibited nutritional or non-nutritional supplements that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results. Prohibited supplements include:\n\n  * a. Mitopure® containing supplements\n  * b. Supplements for muscle strengthening\u002Fbuilding or mitochondrial boosting supplements (e.g. high protein, Vitamin B3 \\[and precursors\\], L-carnitine, CoQ10, NAD+, resveratrol)\n* 12\\. Blood donation in the 8-weeks prior to screening.\n* 13\\. Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the study.\n* 14\\. Participants may not be participating in other clinical studies. If the participant has previously taken part in an experimental study (physical or muscle performance), the Investigator must ensure sufficient time has elapsed before entry to this study to ensure the integrity of the results.","40 Years",{"count":98,"type":22},120,[25],"This is a randomised, double-blind, placebo-controlled, parallel study to assess the effects of Urolithin A (Mitopure®) supplementation on muscle strength and performance in healthy middle-aged adults. Participants will be randomized to consume Mitopure® (500 mg), Mitopure® (1000 mg), or placebo once daily for 6 months.",[36,31],[103],"Urolithin A","2026-03-30",{"date":106,"type":49},"2026-03-31",{"date":108,"type":49},"2025-12-10",{"date":110,"type":22},"2027-10-31",{"name":112,"class":56},"Amazentis SA",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":16,"sex":17,"minAge":65,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":23,"phases":123,"briefSummary":124,"conditions":125,"keywords":128,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":140},"100565720","targeting-aging-with-a-ketone-ester-for-function-in-frailty-100565720","NCT06645847","Targeting Aging With a Ketone Ester for Function in Frailty","A Randomized, Double-blind, Placebo-controlled, Parallel Group, Pilot Study to Evaluate the Effect of a Ketone Ester on Muscle and Immune Function in Older Men and Women Who Are at Risk for Strength and Mobility Decline","TAKEOFF","Inclusion Criteria:\n\n1. Subject is greater than or equal to 65 years of age, inclusive at Screening.\n2. Passes the gait speed criteria at Screening.\n3. Minimum body weight of 50 kgs at Screening.\n4. Subject is willing and able to comply with all study procedures including randomization into any of the experimental groups, maintenance of habitual dietary intake, exercise and medication and supplement use, blood draws and the following prior to test visits: fasting (≥10 h; water only), no alcohol (≥ 10 h), no cannabis products (≥10 h) and no exercise (≥ 10 h).\n5. Subject understands the study procedures and can provide informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Subject is non ambulatory.\n2. Subject has a CSHA clinical frailty score \\> 5.\n3. Subject requires assistance with any activity of daily living, excluding continence.\n4. Subject lives in an institutional setting (skilled nursing facility or residential care facility for the elderly).\n5. Subject is a female who has not passed menopause.\n6. Subject is unable to converse in English (or Spanish, if available at the study site).\n7. Subject has been hospitalized within 30 days of Screening.\n8. Subject has any physical limitation that would prevent them from performing 1RM leg press based on Medical Officer judgement.\n9. Subject has an abnormal laboratory test result(s) of clinical importance at Screening, indicating unstable chronic disease of major organ dysfunction that requires urgent evaluation, at the discretion of the Medical Officer. One re-test will be allowed on a separate day prior to Visit 1, for subjects with abnormal laboratory test results. Additional clinical information may be gathered from the participant if needed to interpret the urgency of laboratory abnormalities (e.g. recent laboratory trends if an electrolyte is abnormal).\n10. Subject has uncontrolled hypercholesterolemia on screening labs.\n11. Subject has a history or presence of acute or uncontrolled and\u002For clinically active pulmonary (chronic obstructive pulmonary disease \\>= Gold 3), cardiac (e.g. \\>= New York Heart Association class III), hepatic (cirrhosis), renal (chronic kidney disease stage \\>= IIIb), endocrine (including type 1 diabetes), hematologic, immunologic, neurologic (e.g., Alzheimer's or Parkinson's diseases), psychiatric (including unstable depression and\u002For anxiety disorders) or biliary disorders. \"Uncontrolled\" and \"clinically active\" are per the judgement of the Medical Officer. Stable chronic disease is not an exclusion criterion unless specified. Chronic disease that is managed with the patient's physician per shared decision-making, even if sub optimally by typically recommended care, is not an exclusion criterion unless uncontrolled or clinically active.\n12. Subject has a clinically important gastrointestinal condition that would potentially interfere with the evaluation of the study beverage \\[e.g., inflammatory bowel disease, irritable bowel syndrome, chronic constipation, severe constipation (in the opinion of the Medical Officer), history of frequent diarrhea, history of surgery for weight loss, gastroparesis, systemic disease that might affect gut motility according to the Investigator, history of gastrointestinal ulcers or bleeding, history of pancreatitis, history of hiatal hernia, history of Barrett's esophagus, or history of esophageal cancer\\].\n13. Heavy drinking (For women, 8 or more drinks per week. For men, 15 or more drinks per week).\n14. Subject has a history of alcohol or substance abuse.\n15. Subject has been instructed not to consume alcohol for medical reasons.\n16. Subject has a known, clinically important allergy, intolerance, or sensitivity to any of the ingredients in the study beverages, including soy and milk protein.\n17. Subject has uncontrolled hypertension as defined by the blood pressure measured at Screening. For subjects with elevated blood pressure at Screening, they are allowed for the purpose of this criteria to submit home readings from three separate days, or to have a repeat reading taken at the study site on a separate day before Visit 1.\n18. Subject is undergoing treatment or active surveillance for cancer or has been diagnosed with cancer in the prior two years, except for non-melanoma skin cancer. Active surveillance is defined as regular imaging or laboratory tests at a frequency greater than annually. Cancer under long-term monitoring such as stable chronic lymphocytic leukemia need not be an exclusion, on the discretion of the Medical Officer.\n19. Immunosuppressive disorders, taking immunosuppressive medications (including oral prednisone \\>10mg\u002Fday and biological immunosuppressants), or receiving chemotherapy.\n20. Chronic antibiotic use (e.g. expected to be ongoing, regardless of frequency, throughout the study period).\n21. Subject has extreme dietary habits (e.g., intermittent fasting or time restricted eating, Atkins diet, vegan, very high protein\u002Flow carbohydrate or has used weight-loss medications (including over-the-counter medications and\u002For supplements) or programs within 30 days of Screening.\n22. Subject has followed a ketogenic diet or used ketone supplements (ketone salts or esters, and medium chain triglycerides) within 30 days of Screening.\n23. Subject has a condition the Medical Officer believes would interfere with their ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results, or put the subject at undue risk.\n24. Subject works nights or shifts that means it is not possible to maintain a consistent meal schedule during the study.",{"count":122,"type":22},180,[25],"This study aims to find out if a food supplement that contains a naturally occurring substance, ketones, can help to improve strength and general wellness in adults at, or over the age of 65 years who are experiencing a slight decline in their physical function.\n\nParticipation will involve a screening visit and 4 additional study visits over the course of 20 weeks. After being assessed for eligibility, study participants will be sorted into two groups at random and consume either a ketone or placebo supplement at home every day for 20 weeks. Both study products can cause gastro-intestinal side effects in some individuals. At all study visits, subjects will provide blood samples. At three study visits, subjects will be asked to complete physical performance tests, provide blood, stool and urine samples. They will also complete questionnaires during three study visits to assess physical function, markers of inflammation, and other aspects of general well-being.\n\nThe study enrolls at three sites across the United States, in California (Buck Institute), Ohio (Ohio State University), and Connecticut (University of Connecticut). The study is coordinated by the San Francisco Coordinating Center (California Pacific Medical Center).",[126,71,127,31],"Frail Elderly","Immune Function",[129,130],"ketone ester","exogenous ketone","2026-03-12",{"date":133,"type":49},"2026-03-13",{"date":135,"type":49},"2025-02-05",{"date":137,"type":22},"2028-04-01",{"name":139,"class":87},"Buck Institute for Research on Aging",3,{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":16,"sex":148,"minAge":149,"maxAge":18,"enrollmentInfo":150,"targetDuration":4,"studyType":152,"phases":4,"briefSummary":153,"conditions":154,"keywords":158,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":166,"leadSponsor":168,"locationsCount":57},"100625465","glp-1ra-effects-on-lean-mass-and-bone-health-in-midlife-women-100625465","NCT07422987","GLP-1RA Effects on Lean Mass and Bone Health in Midlife Women","GLOW","Inclusion Criteria:\n\n* Females\n* Age 35-60 year\n* BMI≥30 or BMI≥27 and at least one cardiometabolic risk factor (dyslipidemia, hypertension, obstructive sleep apnea, metabolic syndrome, fatty liver, PCOS)\n* Newly prescribed a GLP-1RA medication\n* English speaking\n* Body weight stable for the past 6 months\n\nExclusion Criteria:\n\n* Pregnant women\n* Under age 35 or over age 60\n* Born male\n* Cannot consent for themselves\n* Cannot read and speak in English\n* Type 2 diabetes\n* Recently discontinued a GLP-1RA medication (less than 6-months since discontinuing)\n* Contraindications for taking a GLP-1 RA medication (personal or family history of medullary thyroid carcinoma, personal or family history of multiple endocrine neoplasia type 2, personal history of pancreatitis, pregnancy, hypersensitivity to the drug or any component of the drug, active suicidal ideation)\n* Currently taking aromatase inhibitors or selective estrogen receptor modulators (SERMs)","FEMALE","35 Years",{"count":151,"type":22},50,"OBSERVATIONAL","This study is designed with the interest to learn on the effects of estrogen levels and how it affects body compositions and muscle function in midlife women who are taking a GLP-1RA for weight loss.",[155,31,156,157],"Body Composition","GLP-1","Estrogen Level",[159,160,161],"Midlife","Women's health","Dietary quality","2026-02-12",{"date":164,"type":49},"2026-02-20",{"date":162,"type":49},{"date":167,"type":22},"2027-06-30",{"name":169,"class":87},"University of Kansas Medical Center",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":17,"minAge":178,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":23,"phases":181,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":197},"100602976","investigating-the-feasibility-of-krill-oil-intervention-to-improve-muscle-function-in-adults-with-long-term-conditions-100602976","NCT07130513","Investigating the Feasibility of Krill Oil Intervention to Improve Muscle Function in Adults With Long-term Conditions","The Effect of Krill Oil Supplementation on Muscle Function in Adults With High-risk Long-term Conditions: a Randomized Controlled Pilot Study.","KOMM","Inclusion Criteria:\n\n* Men and women aged ≥18 years who are in the high-risk long-term condition group (having one or more LTCs, including rheumatoid arthritis, gout, type 2 diabetes, coronary heart disease, and stroke \\[including transient ischemic attack, TIA\\]).\n\nExclusion Criteria:\n\n* Participants are diagnosed with and being treated for any type of cancer.\n* Presence of neurocognitive disorders or any health condition affecting memory (e.g., Alzheimer's disease, dementia).\n* Aortic stenosis, history of haemorrhagic stroke, or presence of aneurysms.\n* Current anticoagulant therapy.\n* Use of any muscle mass supplements or presence of physiological conditions such as pregnancy or breastfeeding.\n* History of allergy to fish or fish oil.\n* Regular consumption of more than one portion of oily fish per week, or use of fish oil or krill oil supplements.","18 Years",{"count":180,"type":22},30,[25],"This study will recruit 30 adults (men and women, aged 18 years and over) who will be randomly assigned to one of two groups in a 12-week double-blind pilot trial. Participants will receive either:\n\n* Arm 1: Krill Oil group: 4 g\u002Fday of krill oil supplements (Superba™ Antarctic Krill Oil, 1000 mg capsules), or\n* Arm 2: Control group: 4 g\u002Fday of placebo (vegetable oil capsules).\n\nParticipants will be instructed to maintain their usual diet and physical activity patterns throughout the study.\n\nEligibility will be assessed using a health screening questionnaire, completed with the researcher's assistance, before obtaining informed consent. Habitual physical activity will be evaluated using the International Physical Activity Questionnaire (short form), and dietary intake will be assessed with the EPIC Food Frequency Questionnaire (FFQ) at both the beginning and end of the study. In addition, participants will record their fish consumption weekly using a dedicated logbook.\n\nMeasurements will be taken at baseline and after 12 weeks, including:\n\n* Blood samples to assess inflammatory and metabolic markers.\n* Anthropometry and body composition, including weight, height, fat mass, fat percentage, and muscle mass (via ultrasound).\n* Muscle strength, measured using handgrip strength and maximal voluntary contraction (each performed three times with rest between attempts).\n* Physical performance, assessed with a 4-meter walk test at normal speed Upon completing the study, participants will receive a £50 voucher in appreciation of their contribution.",[184,31,185,186,187],"Krill Oil","Grip Strength","Long-Term Conditions","Omega 3 Fatty Acids","2025-10-01",{"date":190,"type":49},"2025-10-02",{"date":192,"type":49},"2025-08-18",{"date":194,"type":22},"2026-07-30",{"name":196,"class":87},"University of Glasgow",2,{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":23,"phases":208,"briefSummary":209,"conditions":210,"keywords":214,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":57},"100564641","the-effect-of-the-nutraceutical----epicatechin-on-myosteatosis-in-patients-with-advanced-ckd-100564641","NCT06631820","The Effect of the Nutraceutical (-)- Epicatechin on Myosteatosis in Patients With Advanced CKD","The Effect of the Nutraceutical (-)- Epicatechin on Myosteatosis in Patients With Advanced CKD: a Pilot Study (EPIC-CKD)","EPIC-CKD","Inclusion Criteria:\n\n* estimated glomerular filtration rate (eGFR) \\\u003C 29 ml\u002Fmin\u002F1.75m2\n* no chronic or acute known liver disease\n* not intended to initiate renal replacement therapy treatment in the next 4 months according to nephrologist clinical judgment\n\nExclusion Criteria:\n\n* signs of active infection\n* acute vasculitis\n* type 1 diabetes\n* use of steroids medication\n* transplanted patients\n* patients with deambulatory impairment (wheelchair users, bed rest)\n* patients on compassionate care for the end of life\n* with advanced neurological disorders\n* with cognitive impairments\n* with active cancer diagnosis\n* participation in another interventional trial.",{"count":207,"type":22},10,[25],"Some foods have components that can prevent and treat some diseases and provide beneficial effects for health. These components naturally occurring in foods are called nutraceuticals. Recently, it was found that Epicatechin, which is a kind of nutraceutical from the Catechin's family naturally occurring in green tea and cocoa, has positive effects on muscle mass and strength of people with chronic diseases.\n\nPeople with chronic kidney disease often present muscle loss and lack of strength that are not easily treated with regular diet and physical activity. We here propose a study where 10 individuals with chronic kidney disease will receive a dose of Epicatechin for 8 weeks and we aim to test if Epicatechin improves general muscle health. Based on what is known, we expect to see an increase in muscle mass and strength.\n\nThe dose of Epicatechin provided (100 mg\u002Fday) is safe, since it is much lower than the dose usually available in supplements. In addition, this is the form naturally present in green tea and cocoa and in similar amounts. Subjects participating in the study will be evaluated for muscle mass and strength three times during the study. Muscle mass and muscle quality will be evaluated by ultrasound and magnetic resonance imaging. The participants will also perform some tests like walking in a corridor and seating and standing from a chair to measure their strength and performance. Adverse side effects will be monitored via telephone, and safety will be assessed by monthly blood tests that will evaluate liver and kidney function. If this study shows that Epicatechin can promote muscle growth and strength, it will positively affect patients with chronic kidney disease that might benefit of a natural substance from food to improve muscle health.",[211,212,213,31,75],"Chronic Kidney Disease(CKD)","Myosteatosis","Mitochondrial Dysfunction",[215,216,217,218,219,220,221],"myosteatosis","epicatechin","nutraceuticals","chronic kidney disease","mitochondrial dysfunction","muscle regeneration","muscle function","2025-07-07",{"date":224,"type":49},"2025-07-10",{"date":226,"type":49},"2025-01-17",{"date":228,"type":22},"2026-10",{"name":230,"class":87},"Karolinska Institutet",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":17,"minAge":178,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":23,"phases":240,"briefSummary":241,"conditions":242,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":57},"100545237","investigating-the-role-of-energy-balance-modification-on-health-responses-in-chronic-lymphocytic-leukaemia-100545237","NCT06379282","Investigating the Role of Energy Balance Modification on Health Responses in Chronic Lymphocytic Leukaemia","HIT-CLL","Inclusion Criteria:\n\n* Confirmed diagnosis of CLL (including small lymphocytic leukaemia) as per the International Workshop on CLL Guidelines.\n* Male or female ≥ 18 years of age\n* Able to walk on a treadmill or cycle on an ergometer\n* Pass the Physical Activity Readiness Questionnaires (PAR-Q and PAR-Q+)\n\nExclusion Criteria:\n\n* Corticosteroid therapy initiated less than 7 days before study entry. Prednisone 10mg or less or equivalent is allowed. Topical or inhaled corticosteroids are permitted.\n* Secondary malignancy within 3 years of study enrollment requiring intervention except for adequately treated basal, squamous cell carcinoma or non-melanomatous skin cancer, carcinoma in situ of the cervix, superficial bladder cancer not treated with intravesical chemotherapy or BCG within 6 months, localised prostate cancer and PSA stable.\n* Absolute contraindications to exercise: Recent (\\\u003C6 months) acute cardiac event unstable angina, uncontrolled dysrhythmias causing symptoms or hemodynamic compromise, symptomatic aortic stenosis, uncontrolled symptomatic heart failure, acute pulmonary embolus, acute myocarditis or pericarditis, suspected or known dissecting aneurism and acute systemic infection.\n* Significant orthopaedic limitations, musculoskeletal disease and\u002For injury. Due to the nature of the study, persons with known joint, muscle or other orthopaedic limitations that restrict physical activity may be excluded.\n* Type I diabetes mellitus or uncontrolled Type II diabetes mellitus, or chronic obstructive pulmonary disease\n* Uncontrolled blood pressure (≥180\u002F90) at rest\n* Known concurrent HIV, Hepatitis B or Hepatitis C\n* Unable to comply with other study requirements",{"count":239,"type":22},132,[25],"This randomised control clinical trial aims to investigate the effects of exercise training and diet on physical and functional fitness and immunological and metabolic changes in adults with chronic lymphocytic leukaemia. Investigators will randomise participants to either 12 weeks of supervised\u002Fsemi-supervised exercise only, exercise + nutritional guidance, or no exercise.",[243,72,31,127,244],"Chronic Lymphocytic Leukemia","Lipid Cell; Tumor","2024-04-23",{"date":247,"type":49},"2024-04-24",{"date":249,"type":49},"2022-10-14",{"date":251,"type":22},"2026-08-01",{"name":253,"class":87},"University of Surrey"]